OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Obesity & Metabolism is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension	266
Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis	200
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications	183
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update	176
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity	169
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review	119
Prediabetes and the risk of heart failure: A meta‐analysis	107
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis	98
Hybrid closed‐loop therapy: Where are we in 2021?	97
Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users	95
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes	93
Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study	76
A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know	68
Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials	67
The PREVIEW intervention study: Results from a 3‐year randomized 2 x 2 factorial multinational trial investigating the role of protein, glycaemic index and physical activity for prevention	66
Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes	66
Obesity as a risk factor for COVID‐19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease	66
Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials	66
Relationship between obesity and severe COVID‐19 outcomes in patients with type 2 diabetes: Results from the CORONADO study	65
Semaglutide for the treatment of overweight and obesity: A review	62
Association of obesity with postacute sequelae of COVID‐19	62
The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc	61
Hybrid closed‐loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double‐blind, multicentre, multinational, randomized, crossover st	59
Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults	58
Association between prediabetes and adverse outcomes in heart failure	58

Predictors of time in target glucose range in real‐world users of the MiniMed 780G system	57
Global mortality of diabetic foot ulcer: A systematic review and meta‐analysis of observational studies	57
Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, ran	56
Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta‐analysis	53
Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested posi	53
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications	52
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin	52
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective	51
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study	51
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials	51
Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, mul	49
Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlle	48
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss	48
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes	47
Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation	47
COVID‐19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission	47
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline cha	46
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes	45
New insights into the treatment of obesity	45
C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective	45
Technology in the management of type 2 diabetes: Present status and future prospects	45